University of Ioannina
Μελέτη του ρόλου του σιδήρου και αξιολόγηση της προστατευτικής ικανότητας σιδηροδεσμευτικών σκευασμάτων με διαφορετική λιποφιλικότητα στην ηπατική βλάβη από ισχαιμία-επαναιμάτωση: πειραματική μελέτη
Abstract
dc:descriptionIschemia and reperfusion (I/R) injury has been defined as the aggravation of cellular dysfunction and death following the reestablishment of blood flow to previously ischemic tissues. Although reperfusion is vital for salvaging ischemic tissues, paradoxically, it also exacerbates tissue injury, depending on the duration and extension of the ischemic event. The reperfusion phase can be divided into the early (<4 h) and the late (4–48 h) reperfusion phase. Tissue injury occurs in both the early and the late phases, but is more severe in the latter. The reperfusion-induced injury occurs in different organs and a wide range of disorders, including myocardial infarction, cerebrovascular disease, hemorrhagic shock, liver resections, trauma and transplantation. Oxidative stress caused by the elevated production of reactive oxygen species (ROS) during reperfusion, represents the critical cause for the development of I/R injury. During the first few minutes of reperfusion, a burst of ROS generation fueled by the reintroduction of oxygen to the previously ischemic tissue occurs, causing tissue injury. ROS include both moderately reactive oxidants (such as O2•- and H2O2) and extremely reactive ones (such as HO•). A necessary requirement for the generation of extremely reactive free radicals is the presence of available labile iron, which acts as a catalyst to convert H2O2 to HO•. This free radical is the most powerful oxidant generated in vivo and provokes uncontrolled oxidations to all basic cellular constituents causing apparent tissue injury. This potential role of iron has been associated with a recently appreciated specific type of iron-dependent cell death, named “ferroptosis”, which invariably accompanies I/R injury. Considering the above, pharmacological interventions that diminish intracellular labile iron during reperfusion could be an alternative effective strategy to protect against the subsequent tissue injury. Tissue labile iron level can be modulated relatively easy by pharmacological means, using exogenous administration of appropriate iron chelating agents. The effectiveness of such drugs depends primarily on their accessibility to the cell interior at the right time and the right concentration. Iron chelating agents have been shown to be very effective in protecting cultured cells against oxidative stress-induced damage and against I/R injury. Based on the above considerations, we hypothesized that the combination of iron-chelating agents of different lipophilicity and iron-binding capacity could increase the possibility to be protective compared to single agents alone. We selected two widely used iron chelating drugs, namely desferrioxamine (DFO) and deferiprone (DFP). The DFO-iron complexes are kinetically favored compared to DFP-iron ones. At the same time, DFP exhibits higher lipophilicity and lower molecular weight and is therefore more capable to penetrate through cell membranes and chelate intracellular labile iron. The contribution of DFO in this system is to abstract iron from DFP-iron complexes in the extracellular space, ultimately acting as a safe sink for available iron.We initially examined whether the combination of the two drugs could offer enhanced protection in cultures of hepatic cells which were exposed to oxidative stress conditions. Our results showed that DFP induced a concentration-dependent decrease in labile iron levels and protected against oxidative stress-induced DNA damage. On the contrary, DFO did not affect iron levels, neither offered any protection to DNA, except when used in a high concentration and long incubation time. Finally, the two drugs in combination showed enhanced protection against DNA damage, compared to the protection offered by DFP alone. Based on these findings, we further performed in vivo experiments in rabbits subjected to partial hepatic ischemia followed by reperfusion. In order to conduct the in vivo part of the experiment and study the late phase of I/R injury, we standardised and described an anaesthetic model of general anaesthesia with endotracheal intubation, followed by recovery of the rabbits, which was applied in the study of the late phase of liver I/R with 24-h follow-up. Animals were subjected to 45 minutes of partial (70%) hepatic ischemia and 24 hours of reperfusion. The above anesthetic model offered hemodynamical and metabolic stability, easy recovery and survival of the animals at 24 hours after reperfusion. We observed in the in vivo part of the experiment that, in accordance with the in vitro experiments pre-treatment of the animals with the combination of the two drugs attenuated I/R-induced hepatic injury. In particular, histological analysis revealed significant protection against hepatocellular injury, while key biochemical markers of hepatic injury (ALT and AST activity) in serum showed a trend to decrease. In addition, the study included an ex vivo part, where liver grafts were subjected to cold ischemia and subsequently to subnormothermic mechanical perfusion with or without the two iron-chelating drugs or their combination. Although the combination of the two agents showed a tendency to liver injury protection, the results were not statistically significant. Both the in vivo and ex vivo experiments included an extra group of animals that were subjected to preconditioning with iron administration intraperitoneally every other day for 10 days. The results were contradictory. Iron-preconditioning showed no protection against warm I/R injury in vivo, but a tendency to protect against cold ischemia and reoxygenation.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Mantelou, Athina
- Μαντέλου, Αθηνά
Subjects
dc:subject × 20- Ηπατική ισχαιμία/επαναιμάτωση
- Οξειδωτικό στρες
- Δεσφεριοξαμίνη
- Δεφεριπρόνη
- Σιδηροδεσμευτικές ενώσεις
- Δραστικές μορφές οξυγόνου (ΔΜΟ)
- Hepatic ischemia reperfusion injury
- Oxidative stress
- Desferrioxamine (DFO)
- Deferiprone (DFP)
- Iron-chelating agents
- Reactive oxygen species (ROS)
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Μεταμοσχεύσεις
- Χειρουργική
- Clinical Medicine
- Medical and Health Sciences
- Transplantation
- Surgery
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60288